About Exact Sciences Corporation (EXAS)

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

EXAS Key Statistics

EXAS Price Performance

Exact Sciences Corporation stock has returned -0.17% over the past day, +0.07% over the past week, +0.09% over the past month, and +1.05% over the past three months. The stock trades between a 52-week low of $38.81 and a high of $103.67.

EXAS Financial Fundamentals

Exact Sciences Corporation reports a return on equity (ROE) of -8.66%, operating margin of -4.79%, profit margin of -640.44%, and revenue growth of +1769.00%. The debt-to-equity ratio is 1.06. Current ratio stands at 2.43.

EXAS Earnings

Exact Sciences Corporation's next earnings report is expected on 2026-05-07 (63 days away). The company has a +0.25% earnings beat rate with an average surprise of -111.68%. Earnings consistency is rated as "low".

EXAS Ownership

Institutional investors hold approximately +0.87% of EXAS shares across 10 institutions. Insider ownership is +0.01%. Insider sentiment is "bearish".

EXAS Short Interest

EXAS has a short interest of +3.78% of float with a short ratio (days to cover) of 3.0.

EXAS AI Analysis Signal

iGotFomo's AI-powered signal engine rates EXAS as "LEAN SELL" with MEDIUM confidence (score: 41/100). 2 signals are bullish, 6 are bearish, and 4 are neutral.